Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Baxter
Merck
Harvard Business School
Colorcon

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,727,253

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,727,253 protect, and when does it expire?

Patent 6,727,253 protects TOTECT and is included in one NDA.

This patent has twenty-two patent family members in sixteen countries.

Summary for Patent: 6,727,253
Title: Treatment of accidental extravasation of anthracyclines
Abstract:The present invention relates to a method for pharmacological treatment of accidental extravasation of topoisomerase II poisons, such as anthracyclines. In particular, the invention relates to the use of a topo II catalytic inhibitor, such as the bisdioxopiperazine ICRF-187, for the treatment of an accidental extravasation of a topoisomerase II poison. A method for treatment of such extravasation of a topoisomerase poison such as the anthracyclines, daunorubicin, doxorubicin, epirubicin, or idarubicin is disclosed.
Inventor(s): Langer; Seppo W. (Gentofte, DK), Jensen; Peter B. (Farum, DK), Sehested; Maxwell (Copenhagen, DK)
Assignee: Antianthra APS (Farum, DK)
Application Number:09/893,521
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,727,253

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Clinigen Hlthcare TOTECT dexrazoxane hydrochloride INJECTABLE;INJECTION 022025-001 Sep 6, 2007 RX Yes Yes   Start Trial   Start Trial TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,727,253

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark1999 00355Mar 12, 1999

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKesson
AstraZeneca
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.